Back to All Events

Blood Products Advisory Committee

On Thursday to Friday, November 30 to December 1, 2017, the Blood Products Advisory Committee (BPAC) discussed and voted on the following topics:

·         Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion;

·         Device classification of human leukocyte antigen, human platelet antigen, and human neutrophil antigen devices; and

·         Strategies to reduce the risk of transfusion-transmitted Zika virus.

The Committee also heard information about the April 6, 2017 FDA public workshop on emerging tick-borne diseases and blood safety, as well as the Transfusion Transmissible Infections Monitoring System.